Barclays initiated coverage of Cognex (CGNX) with an Overweight rating and $55 price target The firm expects Cognex’s EBITDA to recover strongly in 2025, driven by top-line growth and disciplined expense management. Despite recent market downturns, the firm notes Cognex’s continued investment in R&D and sales, reinforcing its leadership in machine vision.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGNX:
- Cognex initiated with an Overweight at Barclays
- Cognex: Balancing AI-Driven Growth Opportunities with Execution Risks and Competitive Pressures
- Cognex initiated with a Neutral at JPMorgan
- ‘AI Stays in Charge’: UBS Suggests 2 AI-Driven Stocks to Buy